Eli Income Statement Research
LLY Stock | USD 745.69 14.36 1.96% |
Eli |
Most accounts from Eli Lilly's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Eli Lilly current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Eli Lilly Valuation and Eli Lilly Correlation analysis. At this time, Eli Lilly's Discontinued Operations is fairly stable compared to the past year. Reconciled Depreciation is likely to rise to about 1.6 B in 2024, whereas Depreciation And Amortization is likely to drop slightly above 994.5 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 21.0B | 21.9B | 27.5B | 28.9B | Total Revenue | 28.3B | 28.5B | 34.1B | 35.8B |
Eli Lilly income statement Correlations
Click cells to compare fundamentals
Eli Lilly Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eli Lilly income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 400.6M | 359.6M | 339.8M | 331.6M | 312.3M | 327.9M | |
Total Revenue | 22.3B | 24.5B | 28.3B | 28.5B | 34.1B | 35.8B | |
Gross Profit | 17.6B | 19.1B | 21.0B | 21.9B | 27.5B | 28.9B | |
Operating Income | 5.0B | 6.1B | 6.4B | 7.1B | 10.3B | 10.8B | |
Ebit | 5.0B | 6.1B | 6.4B | 7.1B | 10.9B | 11.5B | |
Ebitda | 6.6B | 7.6B | 8.7B | 9.4B | 12.5B | 13.1B | |
Cost Of Revenue | 4.7B | 5.5B | 7.3B | 6.6B | 6.6B | 3.6B | |
Income Before Tax | 5.3B | 7.2B | 6.2B | 6.8B | 6.6B | 3.5B | |
Net Income | 4.6B | 6.2B | 5.6B | 6.2B | 5.2B | 2.7B | |
Income Tax Expense | 628M | 1.0B | 573.8M | 561.6M | 1.3B | 810.6M | |
Research Development | 5.6B | 6.1B | 7.0B | 7.2B | 9.3B | 9.8B | |
Non Recurring | 2.8B | 2.5B | 815.2M | 244.6M | 281.3M | 267.2M | |
Minority Interest | 75.7M | 1.1B | 92.2M | 183.6M | 211.1M | 241.8M | |
Tax Provision | 628M | 1.0B | 573.8M | 561.6M | 1.3B | 989.6M | |
Interest Income | 80.4M | 326.6M | 314.4M | 268.8M | 173.6M | 204.8M | |
Net Interest Income | (320.2M) | (326.6M) | (314.4M) | (268.8M) | (312.3M) | (327.9M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Eli Lilly Valuation and Eli Lilly Correlation analysis. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.78 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.